Response Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy
|
|
- Sheena Short
- 5 years ago
- Views:
Transcription
1 2408 Response Predicting Factors to Recombinant Human Erythropoietin in Cancer Patients Undergoing Platinum-Based Chemotherapy Manolo González-Barón 1 Amdio Ordóñez 1 Rosa Franquesa 2 Manuel Constenla 3 Joaquin Montalar 4 Frederic Gili 5 Carlos Camps 6 José Felix Sancho 7 Pedro Pérez-Cachot 8 1 Hospital La Paz, Servicio de Oncología Médica, Madrid, Spain. 2 Hospital General de Vic, Servicio de Oncología Médica, Barcelona, Spain. 3 Hospital Montecelo, Servicio de Oncología Médica, Pontevedra, Spain. 4 Hospital La Fe, Servicio de Oncología Médica, Valencia, Spain. 5 Consorci de l Hospital de la Creu Roja, Servicio de Oncología, Barcelona, Spain. 6 Hospital General Universitario de Valencia, Servicio de Oncología, Valencia, Spain. 7 Hospital Militar Central Gómez Ulla, Servicio de Oncología, Madrid, Spain. 8 Hospital Militar Vigil de Quiñones, Servicio de Oncología, Seville, Spain. Presented at the 23rd ESMO Congress, November 6 10, 1998, Athens, Greece and at the ASCO meeting, May 16 19, 1998, Los Angeles, CA. The authors thank M.A. Arcusa, M.D. (Hospital de Terrasa), M. Boleda, M.D. (Hospital de San Camil), R. Márquez, M.D. (Hospital Clínico de Málaga), and M. Feyjóo, M.D., for their contributions to this study. Address for reprints: Manolo González-Barón, Hospital La Paz, Servicio de Oncología Médica, Paseo de Castellana 261, Madrid, Spain; Fax: ; oncopaz@ene.es Received November 13, 2001; revision received May 24, 2002; accepted July 2, BACKGROUND. The response to epoetin- treatment is hard to predict in cancer patients receiving chemotherapy. METHODS. One hundred and seventeen patients were enrolled in this observational study. They had a hemoglobin (Hb) level less than or equal to 10.5 g/dl, were receiving platinum chemotherapy with three cycles pending, and they did not have an iron deficiency or hemolysis. Epoetin- was administered subcutaneously three times a week at a dose of 150 IU/kg. Ninety patients were examined. RESULTS. Response was defined as an increase in Hb of at least 2 g/dl during the treatment period. The response rate was 63.3%. The following data were compared between responders and nonresponders at the onset of treatment and after 2 and 4 weeks of epoetin therapy: Hb, reticulocytes, serum iron, ferritin, transferrin, transferrin saturation index, and endogenous erythropoietin levels. At baseline, these variables were similar for responders and nonresponders; after 2 weeks, responders showed higher Hb (P 0.001) and transferrin levels (P 0.042) and reticulocyte counts (P 0.003); after 4 weeks, only the Hb level showed a significant difference (P ). Changes from baseline in Hb level after 2 and 4 weeks correlated significantly (P 0.01) with response. The change in Hb level at Week 4 was the best predictor. A change in Hb level of less than 0.5 g/dl was associated with a lack of response (predictive power, 71%); a change in Hb greater than or equal to 0.5 g/dl was associated with response (predictive power, 89%). CONCLUSIONS. Response to epoetin- treatment in cancer patients receiving platinum chemotherapy can be predicted from changes in Hb level after 4 weeks of therapy. Cancer 2002;95: American Cancer Society. DOI /cncr KEYWORDS: platinum chemotherapy, epoetin-, hemoglobin level, response rate. Anemia is the most frequent hematologic disorder among cancer patients, 1 and is generally classified as anemia of the chronic illnesses. Several factors are associated with its origin, including deficiencies in endogenous erythropoietin (EPO) and production in response to a reduction in hemoglobin (Hb) levels compared with patients with iron-deficient anemia. 2 The hypoproliferative state of anemia among cancer patients is related to reduced EPO production or reduced response by the bone marrow. 3 As several studies have shown, the treatment of anemia in cancer patients with recombinant human EPO (epoetin- ) is effective in reducing both the degree of anemia and the need for transfusion in a wide range of tumor types. 4 7 According to currently available data, the percentage of patients responding to treatment with EPO varies depending on which response criterion is used. In the study by Abels 2002 American Cancer Society
2 Predicting Factors to Erythropoietin/González-Barón et al et al., 8 a response (defined as an increase in the hematocrit [Hct] value of six or more percentage points) was observed in 48.4% of the patients, whereas Ludwig et al. 7 identified a response (defined as an increase in Hb of 2 g/dl) in 50% of their patients. Bearing these data in mind, the question remains: Which patient has the greatest chance of responding to the treatment? To provide an answer, Ludwig et al. 9 designed an algorithm to predict the response to treatment with EPO. This algorithm is based on the levels of endogenous EPO and increases in Hb level after 2 weeks of treatment. As an alternative, the ferritin level after 2 weeks of treatment was also shown to be a good response predictor. On the basis of these results, Henry et al. 10 observed that the Hb level after 4 weeks of treatment also had a certain predictive power. However, in both the Ludwig et al. and the Henry et al. studies, the overwhelming majority of cancer patients were not receiving chemotherapy, and of those who were, not all their treatments included platinum. Therefore, these algorithms may not be useful in standard clinical practice (cancer patients with anemia receiving treatment with platinum). For example, the baseline levels of endogenous EPO are subject to changes in patients receiving chemotherapy or radiotherapy. 11 There is no reliable way to predict the response to treatment with epoetin- in patients receiving chemotherapy. 12 The current study analyzed factors that might predict the response to epoetin- under real treatment conditions. This was an open-label, observational, multicenter study of a series of cases. The aims were to identify factors that would predict response after 2 and 4 weeks of treatment with epoetin- and to develop a response algorithm on the basis of these factors. MATERIALS AND METHODS The study included patients who were candidates for treatment with epoetin- who fulfilled the following criteria: age 18 years or older; diagnosis of cancer; on chemotherapy treatment with platinum with three further cycles to be received; Hb levels equal to or below 10.5 g/dl at the beginning of treatment with epoetin; no evidence of uncontrolled high blood pressure, iron-deficient anemia, clinically relevant hemorrhage, or active hemolysis; no packed cell blood transfusion in the week before study entry; and no previous treatment with recombinant human EPO. During the period from 1997 to 1998, this study involved 17 Spanish hospitals and 117 patients, 90 of whom were eligible for analysis (i.e., patients who, once included, continued treatment for at least 4 weeks). The following data were compiled before the first dose of EPO: type of tumor, TNM classification, time since the diagnosis of cancer, existence of bone marrow infiltration, and treatment with cisplatin or carboplatin. If the patient had received previous radiotherapy, total percentage of the body irradiated was also noted. The baseline data required on blood parameters were levels of Hb, Hct, reticulocytes (optional), ferritin, iron, transferrin, and transferrin saturation index. Levels of endogenous EPO were also determined (optional) and the process was centralized at a single laboratory. The same data were recorded after 2 and 4 weeks of treatment with epoetin-. Erythropoietin treatment was given in accordance with the data sheet specifications for the product. The dose of epoetin- was 150 IU/kg, given subcutaneously 3 times a week from entry in the study to 1 month after the end of chemotherapy, unless the physician in charge discontinued treatment sooner. No dose adjustments were made at the fourth week of treatment according to the response obtained. Patients who experienced an increase of at least 2 g/dl in Hb levels during the treatment period were considered to be responders to epoetin-. Study Design The study was nonexperimental and prospective and involved a series of cases. It is an appropriate design for identifying factors that influenced the response to the treatment. Sample Size The Ludwig et al. 9 study identified prognostic factors with a predictive value of about 80%. Because this estimate is based on a total sample of 80 patients, it is subject to a sampling error of 9% (at a 95% confidence level). Our study involved an initial sample of 120 patients to reduce this sampling error and reproduce the results of previous studies with relative accuracy. With the final sample of 90 patients eligible for analysis, we identified prognostic factors with a predictive power of 82%. This estimate is subject to a sampling error of 8%, with a confidence interval of 95%. Therefore, the sample of patients obtained reduces the sampling error of previous studies. An intention-to-treat analysis was performed with all patients who remained on treatment without interruption for at least 4 weeks. In the event of premature interruption or blood transfusion, the last available value was carried forward to 1 month after the end of chemotherapy. The final status of the patient (responder or nonresponder) consisted of the status when the interruption or blood transfusion occurred.
3 2410 CANCER December 1, 2002 / Volume 95 / Number 11 Statistical Analysis The analysis to identify predictive factors consisted of several processes. First, the significant differences between responders and nonresponders were compared with initial patient characteristics. This same analysis was performed with each parameter based on the hematologic data. The chi-square or Fisher exact test, as appropriate, was used to compare significant differences related to categorical variables. For quantitative variables, the Kolmogorov Smirnov test was used to establish the advisability of using nonparametric tests. The Student t test or the Mann Whitney nonparametric test was used according to the result. Second, having established that there were no significant differences between groups as far as initial patient characteristics were concerned, a first attempt was made to find possible predictive factors by correlating data with response and using discriminatory step-wise analysis. The data were correlated with response using biserial correlation. The criterion used in the discriminatory analysis to select variables was based on Wilks lambda. Finally, logistic regression was applied to the data to isolate the factors with the greatest predictive power. These results were used to create models that allowed cutoff points to be established to propose rules for predicting response or nonresponse to treatment with epoetin alfa. The maximum verisimilitude method was used in these analyses. In the regression analysis, the goodness of fit of the models obtained was referred at all times to the available sample of cases. To verify the consistency of the predictive power of the resulting model, six independent random samples extracted from the total number of patients were used, each with a sample fraction of 50% (45 patients). RESULTS Twenty-seven patients were excluded from the analysis for the following reasons: 11 patients due to blood transfusion in the first 4 weeks, 5 patients due to death caused by the malignant disease, 4 patients with fewer than three cycles of chemotherapy pending, and 7 patients for whom no follow-up data for the first 4 weeks were available. There was a 63.3% response rate to epoetin- (defined as an increase of at least 2 g/dl in Hb levels during the treatment period, with no transfusions). The patients basic characteristics are shown in Table 1. None of the variables differed significantly between the two groups of patients as defined by response or nonresponse to treatment with epoetin-. No significant differences were found for the baseline TABLE 1 Baseline Characteristics of Patients Baseline characteristics Responders (n 57) Nonresponders (n 33) Total (n 90) Type of tumor Lung Ovarian Head and neck Bone sarcoma Ewing sarcoma 2 2 Cervix Miscellaneous Mean age (yrs) 55.9 (20 86) 52.9 (18 74) 54.8 (18 86) Gender (%) Men 24 (42.1) 15 (45.5) 39 (43.3) Women 33 (57.9) 18 (54.5) 51 (56.7) Bone marrow infiltration (%) 0 (0) 1 (1.8) 1 (1.1) Previous treatment (%) Surgery 34 (59.6) 16 (48.5) 50 (55.6) Chemotherapy 36 (63.2) 16 (48.5) 52 (57.8) Radiotherapy 2 (3.5) 4 (12.1) 6 (6.6) Mean percent irradiated Previous transfusions (%) 6 (10.5) 1 (3) 7 (7.8) Average time since diagnosis (mos) Current treatment (%) Cisplatin 41 (71.9) 25 (75.8) 66 (73.3) Carboplatin 16 (28.1) 8 (24.2) 24 (26.7) Average no. of cycles received Average total dose received (mg) Cisplatin Carboplatin , , data (Table 2). Differences at the second and fourth weeks are shown in Table 2. The absolute values for Hct (P 0.003), Hb (P 0.001), reticulocytes (P 0.003), and transferrin (P 0.042) after 2 weeks of treatment, and the absolute Hct (P ) and Hb (P ) values at 4 weeks, showed significant differences between the two groups. After 2 and 4 weeks of treatment, the variables that best differentiated between the groups were change in Hct (P ) and Hb (P ) values during both periods. There was also a significant difference in the change observed in transferrin level after 2 weeks (P 0.013; Table 3). Possible Prognostic Factors Analysis of the correlations showed that only six variables correlated significantly with response (P
4 Predicting Factors to Erythropoietin/González-Barón et al TABLE 2 Differences between Groups at Baseline and at the Second and Fourth Week (Response, Nonresponse) At baseline Second week Fourth week Responders Nonresponders P a Responders Nonresponders P a Responders Nonresponders P a Hematology Mean red blood cells ( ) ( ) ns ( ) ( ) ns ( ) ( ) Mean hematocrit (%) 28.2 (20 33) 29.1 ( ) ns 30.6 ( ) 27.9 ( ) ( ) 29.6 ( ) Mean hemoglobin (g/dl) 9.3 ( ) 9.6 ( ) ns 10.1 (6 12.2) 9.2 ( ) ( ) 9.6 ( ) Mean reticulocytes (%) 2.7 ( ) 2.4 (0.1 8) ns 3.4 (0.1 7) 2.1 ( ) ( ) 2.66 ( ) ns Biochemistry Mean serum iron 79.7 (7 450) (10 470) ns 89.1 (6 830) (14 410) ns 83.8 (6 400) 98.1 (9 450) ns Mean ferritin (37 838) (13 962) ns (5 846) (7 819) ns 245 (8 901) 347 (9 999) ns Mean transferrin (79 479) (46 655) ns ( ) (80 343) (80 420) (7 410) ns Mean transferrin saturation index 39.5 ( ) 26.1 (6 56) ns 29.9 (7.3 76) 29.9 (5 76) ns 31.1 (6 84) 29.6 ( ) ns Mean endogenous EPO (mu/ml) 69.1 ( ) 84.0 ( ) ns (33 567) ( ) ns ( ) ( ) ns EPO: erythopoietin. a ns: not significant (P 0.05). TABLE 3 Differences between Groups (Response vs. Nonresponse) Characteristics Baseline values a P values at second week a P values at fourth week a Absolute change after Absolute change after 2 weeks (P) a 4 weeks (P) a Hematology Red blood cells ns Hematocrit (%) ns Hemoglobin (g/dl) ns Reticulocytes (%) ns ns ns ns ns Biochemistry Serum iron ns ns ns ns ns Ferritin ns ns ns ns ns Transferrin ns ns ns Transferrin saturation index ns ns ns ns ns Endogenous EPO ns ns ns ns ns EPO: erythropoietin. a ns not significant (P 0.05) ): change in the number of red blood cells (RBCs) in the fourth week (r ), change in Hct level in the fourth week (r ), change in Hb level in the fourth week (r ), change in the number of RBCs in the second week (r ), change in Hct level in the second week (r ), change in Hb level in the second week (r ), change in Hct level in the fourth week (r ), and change in Hb level in the fourth week (r ). These variables were related solely to the values for Hct and Hb (absolute values in the fourth week and changes observed after 2 and 4 weeks of treatment with epoetin). Of these six variables, the changes in the levels of Hb and Hct showed a correlation of over 0.5. Discriminatory analysis of the results from the correlation analysis confirmed that the variables with significant power to differentiate between responders and nonresponders were absolute Hb values (in the fourth week) and changes observed at 2 and 4 weeks. In addition, the best discriminatory function was constructed with a single variable: the change in Hb level after 4 weeks. The results of the classification matrix pointed to the possibility of using this variable as a prognostic fac-
5 2412 CANCER December 1, 2002 / Volume 95 / Number 11 tor. The discriminatory analysis also showed that the absolute value for Hb level after 4 weeks was a better prognostic factor than the change observed after 2 weeks, in terms of the variance explained. This result was consistent with the high correlation between the change in Hb level after 4 weeks of treatment and the absolute value of Hb at that time (r 0.837). Logistic Regression Multiple logistic regression yielded the same results as discriminatory analysis: the change in Hb values after 4 weeks of treatment was the best prognostic factor to explain the response. In the absence of this variable, the absolute value after 4 weeks was also used as a predictive factor. Conversely, the combination of the absolute value and the change observed in the Hb level after 4 weeks as a first-order interaction was not a significant variable in predicting response. Therefore, the adjusted model identified the change in Hb level after 4 weeks of treatment as the best indicator to explain response to treatment with epoetin. Response Algorithm The model adjusted by logistic regression indicated a change in Hb level after 4 weeks equal to or greater than 0.5 g/dl, as opposed to less than 0.5, as a cutoff point to predict response or nonresponse. The response algorithm estimated response better than nonresponse. The power to predict response to treatment (when the rise in Hb level was 0.5) was 89.1%, whereas the power to predict nonresponse (when the Hb level was 0.5) was 71%. In general terms, the predictive power of the algorithm was high. To verify the consistency of the proposed algorithm, six strictly random samples from the total number of patients studied were simulated. Each sample comprised 50% of the total number of patients. The model adjusted as a result of logistic regression analysis was applied to these samples. Values for Endogenous EPO Table 4 shows the distribution of cases according to the interval of EPO values. There were no significant differences between groups for any of these variables. The correlation with response is extremely low: EPO baseline (r ), EPO second week (r ), EPO fourth week (r ), absolute change in EPO second week (r ), absolute change in EPO fourth week (r ), increase in EPO between the second and fourth week (r ). TABLE 4 Distribution of Cases According to the Interval of Values in mu/ml (Using as a Reference the 100 mu/ml Value Given by Ludwig et al. 9 as a Predictor) Baseline (%) Second week (%) Fourth week (%) Nonresponders (n 23) (n 21) (n 19) or over Responders (n 39) (n 33) (n 28) or over Treatment Times for Patients For all patients, median treatment time was 14 weeks (range, 4 28 weeks). For responders, median treatment time was 14 weeks (range, 4 28 weeks). For nonresponders, median treatment time was 15 weeks (range, 4 26 weeks). Adverse Reactions and Transfusions An adverse reaction occurred in only one patient. This patient started treatment with epoetin- on June 18, On September 10, 1997, the patient suffered moderately severe deep venous thrombosis, possibly related to the study drug. No action was taken with regard to the drug. The symptoms remitted without consequences. DISCUSSION The results of this study add to our current knowledge of factors that predict the response to epoetin-. The factors identified in this study as predictive of the response to epoetin- may be considered useful once treatment has begun (i.e., after 2 or 4 weeks of treatment). The Ludwig et al. 9 study is probably one of the most important studies of predictive factors that can be identified after 2 weeks of treatment. Its prediction algorithm is based fundamentally on changes in Hb and endogenous EPO levels after 2 weeks of treatment, with ferritin levels at 2 weeks as an alternative. However, it is important to point out that the population of patients used to develop this algorithm comprised patients with solid and hematologic tumors who received no concomitant chemotherapy. The criterion for response was an increase of at least 2 g/dl in Hb levels after 12 weeks of treatment. In the current study, a change in Hb level after 4 weeks (increase of at least 0.5 g/dl) was the best indicator of response to treatment with epoetin-. To interpret adequately the response algorithm, the following factors must be considered: the 1) patients had solid tumors and
6 Predicting Factors to Erythropoietin/González-Barón et al were undergoing chemotherapy with platinum and 2) the response to epoetin was defined as an increase in Hb level of at least 2 g/dl during the treatment period. These characteristics of the population and the response criterion may explain why neither the data nor the response algorithm differed from those in the study by Ludwig et al. 9 It is not possible to replicate the EPO curve in the study by Ludwig et al. 9 because no association with response was reported. One of the findings of the current study is that the changes in endogenous EPO did not constitute a factor that predicted response. The absence of differences reflected, in part, the small amount of cases (by the second week, no data were available for 42% of the responders and 36% of the nonresponders). Moreover, the values we obtained are not consistent with those given by Ludwig et al. 9 Ludwig et al. 9 reported that EPO levels remained relatively stable in responders but increased in nonresponders during treatment with EPO. Their average and mean values are consistent with our data between the second and fourth weeks, but not with the baseline values for our patients. This was the reason that led us to analyze the changes between the second and fourth weeks, although this comparison yielded no findings of interest. Conversely,the percentage of our patients with values lower than 100 mu/ml was higher in the group of nonresponders, both in the second and fourth weeks. In the algorithm proposed by Ludwig et al., 9 response was predicted only when EPO was less than 100 mu/ml. We note, however, that with a sample size of 80 patients, a significant correlation (P 0.01) was detectable between EPO levels after the second and fourth weeks and response to treatment. As a result, it is difficult to establish a relationship between EPO levels and response with the data currently available to us. Studies of patients with solid tumors undergoing chemotherapy failed to confirm the predictive value of endogenous EPO levels, 13 which probably explains why we did not find any correlation between this variable and the response to treatment. In a large study of cancer patients, Glaspy et al. 14 showed that the increase in Hb after 4 weeks on epoetin treatment was a useful predictor of final Hb increase. In their study, 75.1% of the patients who achieved an increase in Hb greater than or equal to 1.0 g/dl from baseline to Week 4 had an increase of at least 2.0 g/dl by the end of epoetin treatment. Our response algorithm was similar, although our cutoff value to predict response is 0.5 g/dl. The power to predict nonresponse (when the increase in Hb is 0.5g/dL) estimated in our response algorithm is 71%. We expect to see a response in Hb values in a certain number of patients. However, we have not been able to identify likely responders. When we consider the impact of anemia on the quality of life of cancer patients, the best option at this point is to decide with the patient whether to continue/discontinue epoetin treatment. The availability of a response algorithm for patients receiving treatment undoubtedly improves and targets the use of epoetin- for personalized treatment. In this connection, identifying baseline response factors is of considerable interest to identify those patients who will potentially respond to treatment before treatment is begun. Therefore, the need remains for well designed studies to increase our knowledge of response to treatment in patients with cancer and to allow us to extend the data that we currently possess. REFERENCES 1. Johnson R., Roodman G. Hematologic manifestations of malignancy. Dis Mon. 1989;35: Miller CB, Jones RJ, Plantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;332: Saba Hussain I. Anemia in cancer patients: introduction and overview. Cancer Control. 1998;5(Suppl): Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy induced anemia. Results of double-blind and open-label follow-up studies. Semin Oncol. 1994;2(Suppl 3): Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer. 1993;29(Suppl 2):S2 S8. 6. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9: Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1994;73: Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin for the treatment of the anemia of cancer. In: Murphy MJ. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Dayton, OH: Alpha Medical Press, 1991: Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin in chronic anemia of cancer. Blood. 1994;84: Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin therapy in cancer patients. Blood. 1995;85: Spivak JL. The physiologic basis for the pharmacologic use of recombinant erythropoietin. Cancer Control. 1998;5 (Suppl): Thatcher N. Predicting the response to r-huepo in anaemic cancer patients undergoing chemotherapy. Erythropoiesis: new dimensions in the treatment of anaemia. 1995;6: Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol. 1998;25 (Suppl 7): Glaspy J, Bukowski R, Steinberg D, at al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J ClinOncol. 1997;15:
PREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN. Yves Beguin
PREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN Yves Beguin Senior Research Associate of the National Fund for Scientific Research (FNRS, Belgium). Department of Medicine, Division
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationBC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer
BC Cancer Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer Protocol Code SCESA Tumour Group Physician Contact Pharmacist Contact Supportive Care
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationOriginal article. chemotherapy ranges from 9% to 40% [3]. Anemia related to platinum-containing chemotherapy
Annals of Oncology 9: 255-260. 1998. 1998 Kluwer Academic Publishers. Primed in the Netherlands. Original article Recombinant human erythropoietin in the treatment of chemotherapyinduced anemia and prevention
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationRecombinant Human Erythropoietin for the Treatment of Anemia in Children With Solid Malignant Tumors
Recombinant Human Erythropoietin for the Treatment of Anemia in Children With Solid Malignant Tumors Pedro León, MD,* Miguel Jiménez, MD, Pascual Barona, MD, and Luis Sierrasesúmaga, PhD, FRCP Department
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationFrequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
Year: 2014; Volume: 1; Issue: 1 Article ID: CR14 02; Pages: 1-6 Advances in Cancer Research & Therapy Research Article Frequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
More informationEpoetin 2000 I.U. SEDICO & 4000 I.U. SEDICO & Anemia of Chronic Renal Failure & In Cancer Patients. Anemia of Chronic Renal Failure
SEDICO Newsletter Vol.11 Epoetin 2000 I.U. SEDICO & 4000 I.U. SEDICO & Anemia of Chronic Renal Failure & In Cancer Patients Anemia of Chronic Renal Failure The association of chronic renal failure and
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationRecombinant Human Erythropoietin (rhuepo) for the Treatment of the Anemia of Cancer
Recombinant Human Erythropoietin (rhuepo) for the Treatment of the Anemia of Cancer R. I. ABELS, KAY M. LARHOLT, KENNETH D. KRANTZ, EDWARD C. BRYANT The R.W. Johnson Pharmaceutical Research Institute,
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ES...
Page 1 of 5 Home> Drugs> Drug Safety and Availability> Postmarket Drug Safety Information for Patients and Providers Drugs FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationChronic anemia is a common complication of
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Trends in Hematology/Oncology review haematologica 2002; 87:1209-1221
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationAnemia is a common occurrence in cancer patients, resulting from
1072 Once-Weekly Dosing of Epoetin- Increases Hemoglobin and Improves Quality of Life in Anemic Cancer Patients Receiving Radiation Therapy Either Concomitantly or Sequentially with Chemotherapy Daniel
More informationCPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB
CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB Although relative resistance to the effect of ESAs is a common problem in managing the anemia of patients with CKD
More informationOne of the most important advances in the area of quality of life for
Cancer-Related Fatigue: New Directions for Research Supplement to Cancer 1719 Anemia and Fatigue in Cancer Patients John Glaspy, M.D. Division of Hematology-Oncology, University of California Los Angeles
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors TILMAN
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationAnemia of Chronic Disease
J KMA Special Issue Anemia of Chronic Disease Chul Soo Kim, MD Department of Internal Medicine, Inha University College of Medicine Email : cskimmd@inha.ac.kr J Korean Med Assoc 2006; 49(10): 920-6 Abstract
More informationMHRA Public Assessment Report. Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality.
MHRA Public Assessment Report Epoetins for the management of anaemia associated with cancer: risk of tumour progression and mortality November 2007 Executive summary 2 Introduction 5 Epoetins for treatment
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., a Pfizer company, at , or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT (epoetin
More informationJune 12, Dear Dr. Phurrough:
June 12, 2007 Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Mail Stop C1-09-06 7500 Security Boulevard Baltimore, MD 21244 Dear Dr. Phurrough:
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationPrediction of Response to rhuepo
ESO Scientific Updates, VoL 6 Anaemia in Cancer C. Bokemeyer and H. Ludwig, editors 2001 Elsevier Science B.V. AlI rights reserved 153 Prediction of Response to rhuepo Yves Beguin Research Direclor of
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationPROCRIT (epoetin alfa) for Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT (epoetin alfa)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationUpdates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017
Updates in the Management of Anemia in Cancer Taylor M. Ortiz, MD May 19, 2017 Objectives Recall common causes of anemia in patients with cancer Understand risks/benefits of blood transfusion in patients
More informationA New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study DANIELE SANTINI 1, BRUNO VINCENZI 1, ANNALISA LA CESA 1, VLADIMIR
More informationANEMIA IN CANCER ROLE OF IV IRON
ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional
More informationPharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
British Journal of Cancer (2001) 84 (Supplement 1), 11 16 doi: 10.1054/ bjoc.2001.1747, available online at http://www.idealibrary.com on Pharmacokinetics of novel erythropoiesis stimulating protein (NESP)
More informationManaging Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon. doi: /theoncologist
Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon The Oncologist 2002, 7:331-341. doi: 10.1634/theoncologist.7-4-331 The online version of this article, along with
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationHematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
Hematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy This measure may be used as an Accountability measure Clinical Performance
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005
Generic Brand HICL GCN Exception/Other DARBEPOETIN ALFA IN ARANESP 22890 POLYSORBATE EPOETIN ALFA EPOGEN, 04553 PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005 GUIDELINES FOR USE NOTE: Requirements regarding
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTransfusion. National Clinical Guideline Centre. Blood transfusion. Clinical guideline. November Final version.
National Clinical Guideline Centre 1 Final version Transfusion Blood transfusion Clinical guideline Appendices H-I November 2015 Final version Commissioned by the National Institute for Health and Care
More informationLong Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia
St. Catherine University SOPHIA Master of Arts in Nursing Theses Nursing 12-2012 Long Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia Christine R. Reimer St. Catherine University
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationSymptom Management and Supportive Care
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Symptom Management and Supportive Care Early Intervention with
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationEmilia Parodi, 1 Maria Teresa Giraudo, 2 Fulvio Ricceri, 3 Maria Luigia Aurucci, 4 Raffaela Mazzone, 5 and Ugo Ramenghi 4. 1.
Anemia Volume 2016, Article ID 7345835, 6 pages http://dx.doi.org/10.1155/2016/7345835 Research Article Absolute Reticulocyte Count and Reticulocyte Hemoglobin Content as Predictors of Early Response to
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAs cancer shifts from an inevitable death
CHEMOTHERAPY-INDUCED ANEMIA: TREATING IT AS A DISEASE, NOT JUST A CONDITION J. Michael Hayes, PharmD, RPh * ABSTRACT Anemia related to cancer treatment has multiple etiologies, including bleeding, marrow
More informationIron Deficiency Anaemia but Why? Dr LAU Ching-wa Specialist in Haematology Blood Transfusion Service
Iron Deficiency but Why? Dr LAU Ching-wa Specialist in Haematology Blood Transfusion Service 1 3 Questions 1. Is anaemia incurable in my patient? 2. Is anaemia unavoidable in my bleeding patient? 3. Is
More informationPROCRIT DOSAGE AND ADMINISTRATION PROCRIT
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. injection, for intravenous
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationThree-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Original article Annals of Oncology 13: 1080 1086, 2002 DOI: 10.1093/annonc/mdf186 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study H. Soto Parra
More informationErythropoiesis-Stimulating Agents
Erythropoiesis-Stimulating Agents Policy Number: 5.01.04 Last Review: 8/2017 Origination: 8/2015 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationFactors Potentially Associated with Chemotherapy-induced Anemia in Patients with Solid Cancers
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.10.5057 RESEARCH ARTICLE Factors Potentially Associated with Chemotherapy-induced Anemia in Patients with Solid Cancers Ke Cheng &, Feng Zhao &, Feng Gao, Hang
More informationAnemia Management: Using Epo and Iron
Anemia Management: Using Epo and Iron Ky Stoltzfus, MD University of Kansas Medical Center Assistant Professor Department of Internal Medicine January 23, 2013 Regulation of red cell production Treatment
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationVenous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update
Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Mario Dicato Hematology-Oncology Service, Luxembourg Medical Centre, Luxembourg Key Words. Erythropoiesis-stimulating agents
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia VEENA CHARU,
More informationNew Phase III Clinical Trial Enrolling Now
New Phase III Clinical Trial Enrolling Now Paroxysmal Nocturnal Hemoglobinuria (PNH) Designed for Patients 1. At least 18 years of age 2. With a primary diagnosis of PNH confirmed by high-sensitivity flow
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAlternatives to RBC Transfusion:
Alternatives to RBC Transfusion: beyond Erythropoietin and David Shimabukuro, MDCM Department of Anesthesia and Perioperative Care Medical Director, 13 ICU UC SF 1 Agenda Background Erythropoietin Hemoglobin-based
More informationAnemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor
Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor Email: abdalla.awidi@gmail.com Main Hematological diseases A- Benign Hematology 1- Anemias 2- Bleeding disorders
More informationErythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera )
Erythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera ) Applies to all products administered or underwritten by
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationRecombinant Human Erythropoietin for the Treatment of Chronic Anemia in Multiple Myeloma and Squamous Cell Carcinoma
Recombinant Human Erythropoietin for the Treatment of Chronic Anemia in Multiple Myeloma and Squamous Cell Carcinoma Heinz Ludwig, Martin Pecherstorfer, Clemens Leitgeb, Elke Fritz st Department of Medicine
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationMIRCERA. INN: Methoxy polyethylene glycol-epoetin beta. Pre-filled syringe. Composition
MIRCERA INN: Methoxy polyethylene glycol-epoetin beta Pre-filled syringe Composition Single dose pre-filled syringes: containing 50µg, 75µg, 100µg, 150µg, 200µg, or 250µg methoxy polyethylene glycol-epoetin
More information